Safety of Switching From Rituximab to Ocrelizumab in MS Patients

NCT02980042 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Ocrelizumab
DRUG: Rituximab

Sponsor

University of Colorado, Denver